Alzheimer's Disease Pipeline

DiaGenic’s gene signatures have different applications within the diagnostic work up of Alzheimer’s disease, and the focused portfolio consists of three products. The lead product candidate is aimed to detect Alzheimer’s disease in MCI patients within two years prior to onset of dementia. DiaGenic intends to develop this product, MCItect®, to FDA clearance and has initiated a clinical study in the U.S. DiaGenic also pursues development of two additional AD products; a new generation ADtect® for the detection of mild to moderate Alzheimer’s disease, and AMYtect™ for brain amyloid detection. The exploratory study for AMYtect™ was developed under a collaboration agreement with GE Healthcare.

Alzheimer's Disease Pipeline

  • MCItect® is aimed to detect Alzheimer’s disease in MCI patients within two years prior to onset of dementia.
  • New ADtect® for the detection of mild to moderate Alzheimer’s disease.
  • AMYtect™ for brain amyloid detection. The exploratory study for AMYtect™ was developed under a collaboration agreement with GE Healthcare.